Mestag Therapeutics
Biotech / immuno-oncology & fibrosis, Cambridge
Develops fibroblast-targeted bispecific therapies; lead MST-0312 heading into Phase 1. It raised $40m in a growth round in March 2026. We can't read its job board yet.
Backed by Forbion, GV, Johnson & Johnson Innovation (JJDC) and SV Health Investors. Total raised $95M+.
On the Home Office register of licensed visa sponsors.
Open roles over time
We can't read this company's job board yet.
Hiring momentum
Roles per weekNot tracked yet.
In the news
All 12 stories- LeadershipYahoo Finance, 13 days agoMestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors
- OtherYouTube, 2 Jun 2026Tai Tranagay Begaahan | Singer | Majed Mestag | Poet Haneef Baloch
- OtherGlobeNewswire, 19 May 2026Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
- ProductBusiness Weekly, 18 May 2026'Patient' approach pays off for Mestag as cancer trial begins
- LeadershipPharmafile, 23 Mar 2026Mestag Therapeutics appoints Lindsey Rolfe as Chief Medical Officer and Pascal Merchiers as Chief Development Officer
- Otherbiocentury.com, 18 Mar 2026Clozel resumes CEO role at Idorsia, Mestag builds C-suite